Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2012 | 12-2011 | 09-2011 | 06-2011 | 03-2011 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 61,739 | 70,228 | 74,336 | 67,110 | 90,590 |
| Marketable Securities | 137,356 | 76,174 | 98,685 | 150,839 | 154,050 |
| Receivables | 2,192 | 1,468 | 2,027 | 1,308 | 1,150 |
| TOTAL | $208,539 | $152,028 | $179,957 | $224,334 | $250,709 |
| Non-Current Assets | |||||
| PPE Net | 13,703 | 14,643 | 15,309 | 16,252 | 17,021 |
| Investments And Advances | 117,822 | 114,407 | 114,639 | 99,881 | 100,917 |
| Intangibles | 231 | 0 | 318 | 361 | 405 |
| Other Non-Current Assets | 0 | 839 | 0 | 0 | 0 |
| TOTAL | $131,756 | $129,889 | $130,266 | $116,494 | $118,343 |
| Total Assets | $340,295 | $281,917 | $310,223 | $340,828 | $369,052 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,339 | 5,800 | 5,486 | 7,949 | 5,800 |
| Accrued Expenses | 13,006 | 12,340 | 12,230 | 11,380 | 12,050 |
| Other current liabilities | 275 | N/A | N/A | N/A | N/A |
| TOTAL | $66,638 | $80,990 | $93,927 | $100,534 | $99,344 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 49,018 | 62,850 | 76,211 | 81,205 | 81,494 |
| Other Non-Current Liabilities | 703 | 716 | 729 | 742 | 1,067 |
| TOTAL | $76,279 | $82,930 | $88,423 | $103,743 | $124,141 |
| Total Liabilities | $142,917 | $163,920 | $182,350 | $204,277 | $223,485 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 51,950 | 43,208 | 42,727 | 42,652 | 42,408 |
| Common Shares | 519 | 427 | 427 | 427 | 424 |
| Retained earnings | -412,364 | -400,996 | -386,693 | -373,456 | -359,632 |
| Other shareholders' equity | -37 | -165 | -151 | -246 | -18 |
| TOTAL | $197,378 | $117,997 | $127,873 | $136,551 | $145,567 |
| Total Liabilities And Equity | $340,295 | $281,917 | $310,223 | $340,828 | $369,052 |